BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2024 9:22:48 AM | Browse: 288 | Download: 930
 |
Received |
|
2024-03-13 10:32 |
|
Peer-Review Started |
|
2024-03-13 10:32 |
|
First Decision by Editorial Office Director |
|
2024-05-15 05:34 |
|
Return for Revision |
|
2024-05-15 05:34 |
|
Revised |
|
2024-06-04 14:24 |
|
Publication Fee Transferred |
|
2024-07-01 08:35 |
|
Second Decision by Editor |
|
2024-06-26 02:51 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-26 09:41 |
|
Articles in Press |
|
2024-06-26 09:41 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-08 01:46 |
|
Publish the Manuscript Online |
|
2024-07-11 09:22 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bo Deng, Rui Gao, Bing Yang, Wen-Bing Lei, Ming-Fang Xue, Ji-Shi Wang and Peng Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Science and Technology Foundation of Guizhou Provincial Health Commission |
gzwkj2021-152 |
|
| Corresponding Author |
Peng Zhao, MD, Doctor, Doctor, Department of Hematology, Affiliated Hospital of Guizhou Medical University, No. 28 Guiyi Street, Guiyang 550001, Guizhou Province, China. zhaopeng_6786262@hotmail.com |
| Key Words |
Transplantation; PRCA; Daratumumab; Leukemia; blood-group; Case report |
| Core Tip |
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is currently the only possible way to cure patients with malignant hematologic diseases. In Allo-HSCT, donors have some degree of ABO blood-group incompatibility with the recipient. An outcome of ABO incompatibility caused is pure red cell aplastic anemia (PRCA). We report a 41-year-old female diagnosed with acute myeloid leukemia received a peripheral blood allo-HSCT from an HLA-matched unrelated donor in November 2013. The patient was diagnosed with PRCA three months after allo-HSCT. After failing multiple lines of treatment, daratumumab was requested. After receiving three doses of daratumumab, the patient had a marked reticulocyte response and become transfusion independent.Using of anti-CD38 therapy with daratumumab to target residual host plasma cells is safe and effective, and it can be considered in refractory recipients with PRCA after allo-HSCT secondary to ABO incompatibility. |
| Publish Date |
2024-07-11 09:22 |
| Citation |
Deng B, Gao R, Yang B, Lei WB, Xue MF, Wang JS, Zhao P. Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature. World J Clin Cases 2024; 12(24): 5604-5612 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i24/5604.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i24.5604 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
